出席本次说明会的人员有：公司董事长、总经理杨勇萍先生，董事会秘书顾 永康先生，独立董事黄建春先生，保荐代表人聂晓春女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投 资 者 可 提 前 登 录"互 动 易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入公司本次年度 业绩说明会页面进行提问。届时公司将在本次说明会上对投资者普遍关注的问题 进行回答。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广大投资者积极参与。 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2023-040 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"） 已于 2023 年 4 月 26 日在巨潮资讯网（http://www.cninfo.c ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | |----------------|---------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | | 申万宏源证券（香港）有限公司 詹蔷薇 | | 人员姓名 | 群益投资信托有限公司 杨书婷 | | | 时间 | 10:30 | | | 地点 | 雪榕生物会议室 | | | 上市公司接待人 | | 董秘、副总:王向东 证券代表:靳佩臻 | | 员姓名 | 董秘助理:顾永康（记录） | | | 投资者关系活动 | Q: 请王总介绍行业及产品等情况？ | | | 主要内容介绍 | A | ：食用菌行业是微生物的一支细分行业，公司是 ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | | 国泰投信 李宗谕；野村投信 吴维；中泰证券 夏洲桐；德邦 | | 人员姓名 | | 证券 徐一阳 王力晟；东兴证券 夏立诚 张煜；国信证券 赵冰 | | | | 童；中信建投 秦基粟；群益投资 洪玉婷；海富通基金 刘海 | | | | 啸；中邮基金 黎原；兴业证券 蒋卫华 郭晓琳。 | | 时间 | 8 月 31 日 13:30 | | | 地点 | 雪榕生物一楼会议室 | | | 上市公司接待人 | 董 秘:靳佩臻 | | | 员 ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | |----------------|------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | | | 参与单位名称及 | | 国金证券 钟凯锋；千般资本 朱豪；常春藤资本 石海慧；长 | | 人员姓名 | | 信基金 丁洋；徐星投资 许成；毅鸣投资 柏晓艳 陈琳；瀚伦 | | | 投资 黄志青。 | | | 时间 | 12 月 27 日 | 9:00-11:00 | | 地点 | 雪榕生物一楼会议室 | | | 上市公司接待人 | 董 秘:靳佩臻 | | | 员姓名 | | 证券事务代表：顾永康（活动记录） | | 投资者关系活动 | 1 、观看公司宣传片 | ...

上海雪榕生物科技股份有限公司 投资者关系活动记录 证券代码：300511 证券简称：雪榕生物 | --- | --- | --- | --- | --- | --- | |----------------|---------------------------------------|-------|-------|-----------------|-------| | | | | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | | | | 类别 | □ 媒体采访 □业绩说明会 | | | | | | | □ 新闻发布会 □路演活动 | | | | | | | 现场参观 | | | | | | | □其他 | | | | | | 参与单位名称及 | 1 、大简资本 张敏 2、中金公司 于芝欢 | | | | | | 人员姓名 | 3 、中金公司 孙杨 | | 4 | 、必达控股 张峥 | | | | 5、海通证券 夏越 6、加拿大鲍尔 罗贤润 | | | | | | | 7 、宏信证券 张睿 | | 8 | 、宏信证券 刘冉 | | | | 9、西南证券 徐卿 10、隽诚投资 曹 ...

Group 1: Company Strategy and Market Potential - The company has invested in Beijing Weishida Technology Co., Ltd. and established a joint venture with Aiyi (Xiamen) Food Technology Co., Ltd. to focus on the "plant-based meat" sector, which is still in its early development stage. The Chinese meat market is nearly 3 trillion CNY, and even a 10% share for plant-based meat indicates significant growth potential [2]. - The strategic investments in Weishida and Aiyi are aligned with the company's core business and are expected to enhance growth in the food technology sector [2]. Group 2: Research and Development Focus - Current R&D efforts for plant-based meat (including mushroom protein) are concentrated on improving taste to make it more meat-like, leveraging both local cultural insights and advanced foreign technologies [3]. - Another key focus is on reducing production costs through technological breakthroughs and scaling up production, which is a competitive advantage for the company as the largest edible mushroom producer in China [4]. Group 3: Brand Development and Market Penetration - The company has shifted towards a direct-to-consumer (B2C) model, with small packaging products increasing from 10% to 40% market share within a year, aiming for over 50% by the end of the year [4]. - Brand building has been prioritized since 2019, focusing on penetrating the consumer market through a multi-variety, multi-channel approach, particularly in lower-tier cities [5]. Group 4: Production and Supply Chain Resilience - The company’s factory-based production model for edible mushrooms ensures mechanization and standardization, making it resilient to extreme weather conditions, which has been crucial during recent flooding events [6]. - The current factory production capacity for enoki mushrooms is approximately 900 tons, with the top five companies in the industry accounting for about 60% of production capacity, indicating a significant concentration in the market [7]. Group 5: Future Expansion Plans - The company plans to expand its production capacity with a new facility in Shandong, which will add 100 tons of daily production capacity for enoki mushrooms, even with the potential shutdown of the Shanghai facility [8]. - There are considerations for establishing new bases in underdeveloped regions, such as Central China, to further enhance production capabilities [8]. Group 6: International Operations - The company has established a mushroom factory in Bangkok, Thailand, to tap into the high local market prices and serve surrounding countries with a combined population of 170 million [8]. - Despite delays due to the COVID-19 pandemic, the Thai project is progressing within controllable timelines, with initial daily production capacity set at 66 tons [8]. Group 7: Financial Performance and Market Strategy - The company’s performance in the restaurant sector has improved despite the pandemic, attributed to its transition to a B2C model and strong brand and channel strategies [9]. - The company is preparing to disclose its half-year report on August 27, 2020, while also addressing seasonal fluctuations in the edible mushroom market through robust branding and channel strategies [9].

Financial Performance - The company's revenue for Q3 2022 reached ¥675,808,928.45, representing a 35.03% increase year-over-year[6] - Net profit attributable to shareholders was ¥107,044,675.06, a significant increase of 339.54% compared to the same period last year[6] - The basic earnings per share rose to ¥0.21, reflecting a 310.00% increase year-over-year[6] - Total operating revenue for the current period reached ¥1,649,344,357.67, an increase of 15.4% compared to ¥1,429,298,969.19 in the previous period[24] - The net profit for the current period was a loss of ¥7,016,834.22, an improvement from a loss of ¥143,764,632.81 in the previous period[25] - Total comprehensive income for the current period was a loss of ¥8,314,113.31, compared to a loss of ¥155,792,313.28 in the previous period, indicating a significant reduction in losses[25] Cash Flow - Operating cash flow net amount for the year-to-date was ¥176,348,880.42, up 148.46% from the previous year[12] - Cash flow from operating activities generated a net amount of ¥176,348,880.42, compared to ¥70,975,793.40 in the previous period, indicating a positive trend[26] - The net cash flow from financing activities surged to ¥313,830,951.19, a 3620.84% increase, attributed to funds raised from issuing shares[12] - The total cash and cash equivalents at the end of the period reached CNY 460,946,877.58, up from CNY 310,782,975.99[27] - The company experienced a net increase in cash and cash equivalents of CNY 121,566,461.70, contrasting with a decrease of CNY 449,091,333.34 in the prior period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,590,867,399.61, an increase of 5.78% from the end of the previous year[6] - The company's total liabilities were RMB 2.557 billion, a decrease from RMB 2.686 billion at the beginning of the year[22] - The company's current assets totaled RMB 1.243 billion, up from RMB 874.94 million at the beginning of the year[21] - The company's inventory increased to RMB 464.92 million from RMB 384.08 million at the beginning of the year[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,282[14] - The largest shareholder, Yang Yongping, holds 21.39% of shares, totaling 107,606,850 shares[14] - The company has a diverse shareholder base, including various investment funds and private equity firms[15] - The company is actively managing its shareholder structure to comply with regulatory requirements and enhance shareholder value[16] Investment and Development - The company reported a 927.82% increase in investment income, amounting to ¥14,225,226.09, primarily due to gains from the transfer of subsidiary equity[11] - Research and development expenses decreased by 54.91% to ¥5,607,961.11, mainly due to the shutdown of the Shanghai base[11] - The company acquired a 5% stake in Dafa Xuerong Biotechnology Co., Ltd. for RMB 1.997 million, increasing its total ownership to 69%[18] - The company decided to postpone the Anhui Xuerong Pleurotus eryngii project completion date to August 30, 2024, due to intense market competition and rising raw material costs[18] Regulatory and Compliance - The company has received approval from the China Securities Regulatory Commission for a stock issuance to specific targets, allowing for the issuance of 65,676,567 new shares[17] - The new shares from the specific target issuance were listed on the Shenzhen Stock Exchange on March 21, 2022[17] - The company is subject to lock-up regulations for executives, with Yang Yongping's shares locked for the duration of her tenure[16] Other Financial Metrics - The company reported a short-term loan of RMB 732.68 million, down from RMB 777.49 million at the beginning of the year[22] - The company paid CNY 867,557,375.03 in cash for debt repayment, up from CNY 626,772,839.20[27] - The company reported a foreign exchange impact of CNY 6,657.96 on cash and cash equivalents, compared to a negative impact of CNY -3,616,779.83 in the previous period[27] - The company did not have its third-quarter report audited[28]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥973,535,429.22, representing a 4.82% increase compared to ¥928,810,813.47 in the same period last year[22]. - The net loss attributable to shareholders was ¥100,813,187.17, a 42.59% increase from a loss of ¥70,702,210.37 in the previous year[22]. - The net cash flow from operating activities was -¥14,358,874.35, a decrease of 127.72% compared to ¥51,797,697.21 in the same period last year[22]. - The total assets at the end of the reporting period were ¥4,647,326,566.31, an increase of 7.08% from ¥4,340,128,937.57 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 17.19% to ¥1,959,459,938.11 from ¥1,672,047,546.39 at the end of the previous year[22]. - The basic earnings per share were -¥0.21, a decrease of 31.25% from -¥0.16 in the same period last year[22]. - The diluted earnings per share were -¥0.19, an 18.75% decrease from -¥0.16 in the previous year[22]. - The weighted average return on net assets was -5.57%, a decline of 2.02% from -3.55% in the same period last year[22]. - The company achieved operating revenue of CNY 973.54 million, a year-on-year increase of 4.82%[40]. - The net profit attributable to shareholders was CNY -100.81 million, a decrease of 42.59% year-on-year, primarily due to intense market competition and the impact of COVID-19 on logistics and consumption[40]. - The company reported a net loss from investment income of ¥777,622.30, which constituted 0.67% of total profit[48]. - The total operating revenue for the first half of 2022 was CNY 973,535,429.22, an increase from CNY 928,810,813.47 in the same period of 2021, representing a growth of approximately 4.5%[182]. - The total operating costs for the first half of 2022 amounted to CNY 1,106,396,341.78, up from CNY 1,039,447,123.59 in the previous year, indicating an increase of about 6.4%[182]. - The net loss for the first half of 2022 was CNY 111,544,773.83, compared to a net loss of CNY 89,979,415.46 in the same period of 2021, reflecting a deterioration in performance[184]. Cash Flow and Financing - Cash flow from financing activities increased by 345.49% to CNY 442.09 million, primarily due to funds raised from issuing shares[45]. - The net cash flow from financing activities was 69,133,414.51 CNY, improving from a negative cash flow of -157,313,043.91 CNY in the previous period[193]. - The total cash inflow from financing activities reached 1,111,007,824.02 CNY, an increase from 676,749,527.54 CNY in the prior period[193]. - The cash outflow for debt repayment was 502,000,000.00 CNY, compared to 426,000,000.00 CNY in the previous period[193]. - The company reported a net increase in cash and cash equivalents of 124,806,479.25 CNY, contrasting with a decrease of -177,898,646.29 CNY in the prior period[193]. - The cash and cash equivalents at the end of the first half of 2022 totaled CNY 577.65 million, an increase from CNY 286.33 million at the end of the first half of 2021[191]. Market and Product Strategy - The company operates modern agricultural enterprises focused on the production of edible fungi, with investments in multiple regions including Jilin, Shandong, Guangdong, and Thailand[30]. - Main products include enoki mushrooms, king oyster mushrooms, shiitake mushrooms, and others, emphasizing food safety and high quality[30]. - The company aims to become a leader in the edible fungi industry, focusing on mechanization and standardization in production[30]. - The company has established a pricing management system for both regular and new products, with market analysis conducted weekly[36]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by the end of 2023[200]. - The company has initiated a strategic partnership with a leading biotech firm to enhance its product offerings and technological capabilities[200]. Research and Development - Research and development expenses decreased by 61.90% to CNY 3.08 million, mainly due to the shutdown of the Shanghai base[44]. - Research and development expenses for the first half of 2022 were CNY 3,082,989.11, down from CNY 8,091,916.41 in the same period of 2021, a decrease of about 61.9%[183]. - Research and development expenses for the first half of 2022 were 150 million yuan, accounting for 10% of total revenue, aimed at new product development[200]. Environmental and Social Responsibility - The company has established an environmental monitoring plan and engages third-party agencies for regular monitoring of major pollutants to ensure compliance with discharge standards[90]. - There were no administrative penalties due to environmental issues during the reporting period[91]. - The company continuously improves its environmental protection and pollution prevention systems, ensuring efficient operation of environmental facilities without major pollution incidents[88]. - The company actively participates in social welfare activities, including blood donation and support for the elderly, contributing to community development[94]. - The company has invested in poverty alleviation projects in key areas, achieving significant social benefits and recognition for its contributions[95]. - The company prioritizes employment for impoverished households and provides training to enhance their skills, ensuring sustainable poverty alleviation[96]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the half-year period[81]. - The company approved the repurchase and cancellation of 4.556 million restricted stocks held by 167 incentive objects at a price of RMB 3.98 per share, totaling RMB 18,264,525.19 paid in cash[82]. - The company’s stock incentive plan will continue to be executed in accordance with regulatory requirements[84]. - The company has a diverse shareholder base, with significant holdings from various private equity funds[149]. - The report indicates that there are no related party transactions or concerted actions among the top shareholders[150]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[108]. Risks and Challenges - The company faces risks such as intensified market competition leading to price declines and fluctuations in raw material prices[4]. - The company has faced challenges in the edible mushroom market due to intense competition and fluctuating prices, impacting profitability[62]. - Raw material prices have increased during the reporting period, affecting procurement costs; the company aims to optimize its substrate formula and production processes to mitigate cost increases[72]. - The company anticipates potential declines in gross margin and profits if product prices continue to fall and cost reduction efforts are insufficient[73]. - Seasonal fluctuations in sales prices and profits are evident, with the lowest prices typically occurring in Q2 and Q3, while Q1 and Q4 see higher prices due to increased demand[73].

Financial Performance - The company's revenue for Q1 2022 was ¥575,916,010.18, representing a 1.66% increase compared to ¥566,499,913.52 in the same period last year[3] - Net profit attributable to shareholders decreased by 43.38% to ¥57,397,068.93 from ¥101,367,147.34 year-on-year[3] - Basic earnings per share fell by 45.83% to ¥0.13, compared to ¥0.24 in the same period last year[3] - The total comprehensive income for Q1 2022 was ¥60,304,994.90, down from ¥93,107,824.21 in the same period last year, indicating a decrease of about 35.3%[23] - Net profit for the quarter was CNY 60,526,964.61, compared to CNY 96,052,419.32 in the same period last year, reflecting a decrease[22] Cash Flow - The net cash flow from operating activities dropped by 61.55% to ¥36,207,316.24, down from ¥94,171,489.26 in the previous year[3] - Cash inflows from operating activities totaled ¥567,609,702.47, slightly up from ¥566,819,501.52 in the previous year, showing a marginal increase of 0.14%[26] - Cash flow from investing activities resulted in a net outflow of ¥102,660,123.39, an improvement from a net outflow of ¥314,263,474.03 in the previous year[27] - Cash flow from financing activities generated a net inflow of ¥435,119,938.32, compared to a net outflow of ¥83,470,634.71 in Q1 2021, indicating a significant turnaround[27] Assets and Liabilities - Total assets increased by 4.56% to ¥4,747,152,356.00 from ¥4,539,961,256.98 at the end of the previous year[3] - Total liabilities decreased slightly to CNY 2,642,700,976.17 from CNY 2,685,582,068.16[19] - The company's equity attributable to shareholders increased to CNY 2,118,878,936.05 from CNY 1,672,047,546.39, reflecting a growth of 26.73%[19] - Long-term borrowings rose to CNY 520,547,357.44 from CNY 392,496,781.30, an increase of 32.66%[19] Shareholder Information - The company issued a total of 65,676,567 shares of ordinary stock to 11 specific investors, which were listed on the Shenzhen Stock Exchange on March 21, 2022[15] - The total number of restricted shares at the beginning of the period was 106,622,182, with 4,311,302 shares released from restriction during the period[14] - The company has 80,523,787 restricted shares held by Yang Yongping, which are locked due to executive restrictions[13] - The top 10 unrestricted shareholders hold a total of 80,523,787 shares, with Yang Yongping and Zhejiang Yinwan Stere Investment Management Co., Ltd. being the largest shareholders[12] Research and Development - Research and development expenses decreased by 61.62% to ¥1,826,764.99, primarily due to the shutdown of the Shanghai base[6] - The company has not reported any new product launches or technological advancements in this quarter[16] Other Income and Expenses - Other income related to government subsidies decreased by 51.82% to ¥6,462,755.79 compared to the previous year[7] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -¥133,181.83 compared to -¥1,906,383.46 in the previous year[23] Audit Information - The company did not conduct an audit for the Q1 2022 report[28]